Mayer Brown Assists SERB Pharmaceuticals in Acquiring Idefirix® Rights from Hansa Biopharma
Mayer Brown LLP has advised SERB Pharmaceuticals on its agreement to acquire exclusive rights for the development and commercialization of Idefirix® (Imlifidase) across multiple key markets, including the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and the MENA region.